Eradication therapy using antibiotics is often effective against gastrointestinal (GI) mucosa--associated lymphoid tissue (MALT) lymphoma. More than 90% of gastric MALT lymphoma cases are associated with *Helicobacter pylori* (HP) infection, and 75% of them regress after HP eradication[@b1]. In addition to MALT lymphoma, some cases of rectal MALT lymphoma and gastric diffuse large B-cell lymphoma (DLBCL) show regression as a result of HP eradication therapy[@b2][@b3][@b4][@b5], suggesting that development or progression of GI lymphoma is affected by the host inflammatory microenvironment or immune reactions. MALT lymphoma is the most frequent subtype in the stomach, whereas follicular lymphoma (FL) is most common in the duodenum[@b6][@b7]. Studies have shown that in contrast to the nodal subtype, intestinal FL shares characteristics with MALT lymphoma such as clinicopathological features, immunoglobulin repertoire, and gene expression[@b7]. This observation suggests that an immune reaction to some stimuli may have role in the tumor development or progression of intestinal FL.

Proinflammatory cytokines produced by helper T cells (Th) regulate immune reactions, and it is known that they facilitate class switching of B cells and prolong the lifespan of B and T cells[@b8]. Among patients with HP-related gastritis, several Th1/Th2 cytokines elevations were reported[@b9]. As for malignant lymphoma, relationship with Th1/Th2 cytokine profile is not well elucidated. In the present study, we tested the hypothesis that the profiles of serum Th1/Th2 cytokines of various lymphoma subtypes differ according to subtypes. We then focused on GI low-grade B-cell lymphoma, particularly FL and MALT lymphoma.

Results
=======

Serum interleukin (IL)-8, IL-4 and IL-1β levels were different depending on a lymphoma subtype
----------------------------------------------------------------------------------------------

Among the 11 analyzed cytokines, IL-8, IL-4, and IL-1β levels were significantly different from control depending on the lymphoma subtype using one-way analysis of variance among control and lymphoma subtypes (*P* = 6.69E−05, 7.46E−05, and 0.0043, respectively; [Table 1](#t1){ref-type="table"}). These three cytokines were also significantly different among the lymphoma subtypes (*P* = 1.63E−04, 1.15E−04, and 0.0040, respectively; [Table 1](#t1){ref-type="table"}). When we limited the analysis to three major subtypes (DLBCL, FL, and MALT lymphoma) and subdivided the cases by the presence or absence of GI lesions, these three cytokines also showed serum levels significantly different from controls using one-way analysis of variance among control and lymphoma subtypes (*P* = 0.0039, 0.00019, and 0.024, respectively; [Table 2](#t2){ref-type="table"}). These three cytokines were also significantly different among the lymphoma subtypes (*P* = 0.021, 0.00076, and 0.045, respectively; [Table 2](#t2){ref-type="table"}).

Serum IL-8 level was elevated in GI low-grade B-cell lymphoma
-------------------------------------------------------------

The serum IL-8 level was elevated in FL and MALT lymphomas with GI lesions (*P* = 0.0039; [Fig. 1A,B](#f1){ref-type="fig"}), and there was no difference between these two subtypes with GI lesions (*P* = 0.25; [Fig. 1A](#f1){ref-type="fig"}). In FL, the serum IL-8 level in cases with GI lesions was higher than that in cases without GI lesions, but in MALT lymphomas, there was no difference between cases with and without GI lesions ([Fig. 1A](#f1){ref-type="fig"}). Although the IL-8 value was higher in GI(−)DLBCL than in GI(+)DLBCL, it was not significantly different (*P* = 0.138).

As for the 17 GI-FL, 16 nodal FL, and 10 GI-MALT lymphoma cases, interleukin-8 receptor β (IL-8RB) (CXCR2) protein expression was assessed using immunohistochemical analysis. Among the FL cases, IL-8RB expression was frequently observed in GI-FL cases (GI-FL: 17/17, nodal FL: 8/16; *P* = 0.0093; [Fig. 2A,B](#f2){ref-type="fig"}), whereas all MALT lymphoma cases showed expression of IL-8RB ([Fig. 2C](#f2){ref-type="fig"}). This result meant that the receptor of IL-8 was expressed in tumor tissue.

Serum IL-4 and IL-1β levels were elevated in GI-MALT lymphoma cases
-------------------------------------------------------------------

Serum IL-4 and IL-1β levels were elevated in MALT lymphoma cases compared with healthy controls (*P* = 0.00019 and 0.024, respectively; [Figs 3](#f3){ref-type="fig"}A and [4](#f4){ref-type="fig"}A). Both cytokines were also elevated when we analyzed only serum samples from MALT lymphoma cases with GI lesions ([Figs 3](#f3){ref-type="fig"}B and [4](#f4){ref-type="fig"}B). In MALT lymphoma cases, the serum levels of both cytokines were not linked to the presence of GI lesions (*P* = 0.39 and 0.40, respectively; [Figs 3](#f3){ref-type="fig"}A and [4](#f4){ref-type="fig"}A). Similarly, IL-4 and IL-1β were higher in GI−DLBCL than in GI+DLBCL, but they were not significantly different (*P* = 0.410, 0.045, respectively).

Discussion
==========

IL-8 (CXCL8) was first identified as a neutrophil chemoattractant that belongs to the CXC chemokine family[@b10]. IL-8 is a proinflammatory chemokine and an angiogenic factor that mediates various inflammatory responses and is associated with tumor progression[@b11]. In non--small cell lung carcinoma, IL-8 is overexpressed under the influence of KRAS and enhances the stromal response by inducing inflammation and angiogenesis, which are associated with tumor proliferation and negatively correlate with patients' survival[@b12].

After antigen stimulation in the Peyer's patch, B cells undergo class switching to IgA expressing α4β7 integrin and then home to the intestine via MAdCAM-1, which is expressed on endothelial cells of intestinal blood vessels[@b13]. Judging by the gene expression analysis reported previously, MAdCAM-1 and CCL20 were overexpressed in FL and MALT lymphoma tissue of the GI tract compared with the nodal counterpart[@b14]. This overexpression of MAdCAM-1 may be caused by the IL-8--induced angiogenesis.

IL-4 is produced by Th2 cells, mast cells, and basophils and activates the JAK/STAT and PI3K pathways. In addition to the association of IL-4 with inflammatory responses and allergic reactions, B cells express IL-4 receptor, which promotes their proliferation as a co-mitogen, controls class switching to IgE or IgG4, and prolongs the cellular lifespan. IL-4 also makes B cells express THY1 by associating with lipopolysaccharides[@b8][@b15]. IL-1β is a component of the IL-1 complex and is linked to several inflammatory processes by activating macrophages. In addition to IL-8, we examined IL-4 receptor α (IL-4RA) immunostaining on 30 cases (10 GI FL, 10 nodal FL, and 10 GI MALT). In contrast to IL-8RB, IL-4RA was weakly positive for more than half of the cases regardless of the subtypes (*P* = 0.63) and was not reflected high serum IL-4 value in MALT lymphoma. (data not shown) It is suggested that IL-4 acts indirectly on tumor cells. Unfortunately an adequate level of IL-1 receptor antibody was not available.

HP is known to be a major factor in the MALT lymphoma development. According to some researchers who performed cytokine expression analysis of HP-related and HP-unrelated gastritis, several Th1/Th2 cytokine combinations participate in the HP-related inflammation[@b9]. Elevation of IL-4, IL-8, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ levels was also observed. In HP-related gastritis caused by the CagA-positive strain, elevation of IL-1β and IL-18 levels was reported[@b9].

In the present study, elevation of IL-4, IL-1β, and IL-8 levels was detected in MALT lymphomas. This change may be caused by the HP-related inflammation. In another report, IL-4 production was found to be increased when a patient's peripheral blood mononuclear cells (PBMCs) were stimulated by HP hsp60 or HP lysate[@b16]. Gene pleomorphism of the IL-4 gene and IL-1 receptor antagonist (IL-1RN) gene was reported to negatively correlate with HP-related gastric cancer[@b17], suggesting that reactivity to such cytokines is linked to tumor development. In the present study, the correlation of HP infection with changes in cytokine production was not observed probably because of the insufficient sample size ([Supplementary Figure](#S1){ref-type="supplementary-material"}).

When confined to low-grade B-cell lymphoma, most of the cases were primary GI cases and a few cases were those of secondary GI involvement in this study. We could not examine if there were any clinicopathological differences between the primary and secondary cases because the number of secondary cases was a few. However, it is suggested that the cytokine profiles shown in this study reflected those of primary GI low-grade B-cell lymphoma.

Although the main lesion of primary GI FL is often in the duodenum, total GI tract screening using double-balloon endoscopy revealed that 85% of the cases had lymphoma lesions that were broadly located in the GI tract[@b7]. In addition, some cases of MALT lymphoma of the stomach have concomitant lesions in the duodenum or colon. In our series, there was small number of patients whose GI lesion restricted to single organ were 6 cases (all stomach cases) for MALT, 13 (duodenum: 10, ileum: 3) for FL, 7 (stomach: 5, ileum: 1, colon: 1) for DLBCL. Considering these facts, HP +/− gastritis patients were not necessarily fit as adequate controls for this study as well as the inflammatory disease patients affecting corresponding organs, such as duodenitis, ileitis and colitis, because comparison among other subtypes, would be difficult. Therefore, we included healthy subjects as the controls in this study.

It was reported that the clinical behavior of the GI FL cases was very indolent, similar to MALT lymphoma but in contrast to that of the nodal type[@b7][@b18]. Moreover GI FL was reported to have similar characteristics with MALT lymphoma, both in the immunohistochemical and molecular aspects including gene expression profiles[@b14][@b19]. In the present study, GI FL and MALT lymphoma had similar elevations in serum IL-8; to discriminate MALT from GI FL, IL-4 and 1β elevations could be used. In this study, the functions of the cytokines indicated for the specific lymphoma subtypes were not investigated and warrant further study. For example, lymphoma development under the influence of specific cytokines using transgenic mice holding t(14;18) needs to be examined. To our knowledge, there is no report analyzing the proinflammatory cytokine profiles that are specific for GI lymphoma, and we believe that the relevance of this study is in the discovery of important serum cytokines, which could be the factors involved in the pathogenesis of lymphoma.

In summary, analysis of Th1/Th2 cytokine levels in serum samples shows that IL-8 levels were elevated in GI FL and MALT lymphomas, whereas IL-4 and IL-1β levels were elevated in MALT lymphomas. These results show that GI low-grade B-cell lymphoma probably develops in an inflammatory microenvironment. This finding needs confirmation with a larger sample size, particularly for the utility of these cytokines as auxiliary diagnostic biomarkers. Further studies of the mechanisms involving these cytokines in the tumor microenvironment would be warranted and may lead to new therapeutic targets.

Methods
=======

Clinical samples
----------------

Serum samples from 148 patients with malignant lymphoma were collected at our collaborating hospitals: Gifu University Hospital (June 2004--March 2012), Gifu City Hospital (March 2010--April 2015), and Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital (June 2011--May 2012). The samples from the patients included in this study are described in [Table 3](#t3){ref-type="table"}. The patient age had a median age of 62 years (range 41--83 years), and the male to female ratio was 16:15. Serum samples for all cases, except three, were taken before treatment. The three cases were as follows: 1 mantle cell lymphoma (MCL), 1 Hodgkin lymphoma (HL), and 1 MALT lymphoma (HP eradication therapy alone). The other clinical characteristics were obtained from 31 cases. The numbers of serum samples corresponding to each lymphoma subtype were as follows: 55 cases of DLBCLs including 2 intravascular large B-cell lymphomas (IVL), 36 FLs, 15 MALT lymphomas, and 42 other lymphomas (2 angioimmunoblastic T-cell lymphomas, 2 adult T-cell leukemias/ lymphomas, 2 acute lymphoblastic leukemias, 2 non-HLs, 2 Burkitt lymphomas, 1 hairy cell leukemia, 1 hepatosplenic T-cell lymphoma, 5 HLs, 3 MCLs, 4 natural killer (NK)/T-cell lymphomas, 15 peripheral T-cell lymphomas, 2 small lymphocytic lymphomas, and 1 cutaneous follicle center lymphoma). Serum samples from 21 healthy volunteers served as controls. Approval for the study protocol was obtained from the institutional review board at Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and similar boards at the collaborating hospitals. Informed consent was obtained from all subjects. All study procedures were conducted in accordance with the guidelines of the Declaration of Helsinki. In our hospital and other collaborating centers, diagnosis was based on the current WHO classification using appropriate immunostaining, such as CD20, 10, 5, BCL2, and cyclinD1 for low-grade B-cell lymphoma, and CD20, 10, and 5 for DLBCL[@b6]. In the analysis comparing the presence of GI lesions in DLBCL, FL, and MALT, cases of IVL (n = 2) and composite MALT and DLBCL (n = 1) were excluded. The behavior of composite MALT and DLBCL could not be investigated with a low sample number. Relevant information concerning involved sites was obtained from 81 out of 106 cases of major 3 subtypes (DLBCL, FL, and MALT). Among them, 37 had GI lesions and 28 of these were primary sites of lymphoma (case numbers of "primary GI cases" and "cases with secondary involvement or suspicious for secondary involvement of the GI tract" were 1 and 7 for DLBCL, 17 and 1 for FL, and 10 and 1 for MALT lymphoma, respectively).

Cytokine analysis
-----------------

Eleven kinds of cytokines \[IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-α, and TNF-β\] were analyzed using the FlowCytomix Human Th1/Th2 11plex Kit BMS810FF (eBioscience, Vienna, Austria) and MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany).

Immunohistochemical analysis
----------------------------

Biopsy samples were fixed in 10% buffered formalin embedded in paraffin blocks and subjected to immunohistochemical analysis as described previously[@b20]. The clone of the antibody and dilution were 48311 and 1:100 for IL-8RB, and 25463 and 1:500 for IL-4RA, respectively (R&D Systems, Inc., Minneapolis, USA).

Statistical analysis
--------------------

One-way analysis of variance was used. For statistical tests *P* \< 0.05 was set as significant.

Additional Information
======================

**How to cite this article**: Miyata-Takata, T. *et al.* Elevation of serum interleukins 8, 4, and 1β levels in patients with gastrointestinal low-grade B-cell lymphoma. *Sci. Rep.* **5**, 18434; doi: 10.1038/srep18434 (2015).

Supplementary Material {#S1}
======================

###### Supplementary Figure

The authors thank Central Research Laboratory, Okayama University Medical School for technical assistance. This work was supported by a grant from the Japan Society for the Promotion Science (JSPS no. 23590398 and 24790350).

**Author Contributions** K.T., T.M.-T. and T.Y. designed this study and wrote the manuscript. K.T. and T.T. performed the experiment and analyzed the data. T.M.-T., M.N.-H., T.M., Y.S. and T.Y. analyzed the data, N.G., S.K., T.T. and A.T. provided the case.

![Serum IL-8 level according to lymphoma subtype and with/without GI lesions.\
(**A**) Serum IL-8 level was elevated in GI FL and MALT lymphomas. The IL-8 level was elevated in FL with GI lesions, but not in MALT lymphomas. (**B**) Among cases with GI lesions, serum IL-8 was elevated in FL and MALT lymphomas. There was no difference between FL and MALT lymphomas with GI lesions. IL: interleukin, GI: gastrointestinal, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.](srep18434-f1){#f1}

![Immunohistochemical analysis of IL-8RB in representative FL and MALT lymphoma cases.\
Intestinal FL (**A**) and gastric MALT lymphoma (**C**) tested positive for IL-8RB, but nodal FL tested negative (**B**). IL-8RB: interleukin-8 receptor β, GI: gastrointestinal, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.](srep18434-f2){#f2}

![IL-4 serum levels by lymphoma subtypes and with/without GI lesions.\
(**A**) Serum IL-4 levels were elevated in MALT lymphomas regardless of GI lesions. There were no differences between MALT lymphomas with and without GI lesions. (**B**) Among cases with GI lesions, serum IL-4 level was elevated in MALT lymphomas. IL: interleukin, GI: gastrointestinal, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.](srep18434-f3){#f3}

![Serum IL-1β levels by lymphoma subtypes and with/without GI lesions.\
(**A**) Serum IL-4 levels were elevated in MALT lymphomas regardless of GI lesions. There was no significant difference between MALT lymphomas with and without GI lesions. (**B**) Among cases with GI lesions, the serum IL-1β level was elevated in MALT lymphomas. IL: interleukin, GI: gastrointestinal, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.](srep18434-f4){#f4}

###### Cytokine values according to each histological subtype.

             Subtype (n)   DLBCL (55)   FL (36)    MALT(15)   Others (42)   (pg/ml)      *P\**         *P\*\**
  --------- ------------- ------------ ---------- ---------- ------------- --------- -------------- --------------
  IL8          Median       180.193     462.404    1340.327     159.927     88.731    **6.69E-05**   **1.63E-04**
  SD           341.955      667.029     2634.167   287.289      188.895                             
  IL4          Median        18.919      6.189     137.726      26.983      10.565    **7.46E-05**   **1.15E-04**
  SD           56.707        32.751     238.447     69.04       43.259                              
  IL1β         Median        2.906       13.856     79.461       7.408       6.061     **0.0043**     **0.0040**
  SD           17.617        49.704     211.445     24.653      27.775                              
  IL12p70      Median        26.78       0.753      11.067      120.256     26.915        0.65           0.54
  SD           185.671        4.52       31.793    715.009      87.175                              
  IFNγ         Median        22.305        0        7.679       217.567        0         0.076           0.07
  SD            99.65          0         24.516    787.469         0                                
  IL2          Median        30.463      29.98      54.789      28.705       29.6         0.97           0.92
  SD           168.096       64.583     142.198    117.611      135.642                             
  IL10         Median       814.164      1.696      13.149      105.894      2.161        0.31           0.28
  SD          3733.864       4.765       23.435    401.716       9.905                              
  IL6          Median        31.509      7.834      21.831      17.632       1.169        0.73           0.77
  SD           155.883       29.162      75.664     68.259       5.357                              
  IL5          Median        16.509      1.856      11.153      13.955       1.021        0.82           0.81
  SD           104.195       10.185      43.197     57.841       4.679                              
  TNFα         Median        2.117       19.336     32.285      19.269       3.104        0.14           0.15
  SD           11.309        78.945      71.478     50.049      14.226                              
  TNFβ         Median          0         2.875        0          5.419      14.509        0.39           0.54
  SD              0          17.252        0        32.034      66.487                              

DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue lymphoma

\**P* values were calculated among lymphoma subtypes and normal controls.

\*\**P* values were calculated among lymphoma subtypes.

###### Cytokine values of each lymphoma subtype according to presence or absence of gastrointestinal lesion.

  Subtype     DLBCL       FL       MALT     (pg/ml)    *P\**     *P\*\**                                    
  --------- --------- ---------- --------- --------- ---------- ---------- --------- -------- ------------- -------------
  IL8        Median     48.626    304.683   777.218   150.861    1662.842   453.41    88.731   **0.0039**     **0.021**
  SD         62.874    469.097    797.085   273.918   3044.377   238.565    188.895                         
  IL4        Median       0        9.638     2.871     10.194    170.979     46.28    10.565   **0.00019**   **0.00076**
  SD            0       32.315    12.179    42.031     269.2      92.56     43.259                          
  IL1β       Median       0        1.422       0       29.342    108.355       0      6.061     **0.024**     **0.045**
  SD            0       6.821        0      70.153    243.205       0       27.775                          
  IL12p70    Median     5.565     59.874     1.507       0        15.092       0      26.915      0.86          0.823
  SD          15.74    287.145     6.392       0       36.72        0       87.175                          
  IFNγ       Median       0       43.767       0         0        10.471       0        0         0.41          0.502
  SD            0      150.935       0         0       28.448       0          0                            
  IL2        Median       0       64.992    39.635     22.088     74.713       0       29.6       0.89          0.841
  SD            0      258.524     73.37    57.087    163.312       0       135.642                         
  IL10       Median    236.965    1453.79    0.149     3.433      15.176     7.573    2.161       0.56          0.619
  SD         529.503   5665.383    0.634     6.57      26.136     15.145     9.905                          
  IL6        Median       0       21.623     6.078     10.155     29.176     1.633    1.169       0.53          0.699
  SD            0        59.4      9.903    41.751     88.258     3.265      5.357                          
  IL5        Median     0.254     39.062     3.389     0.343      15.209       0      1.021       0.68          0.735
  SD          0.718     160.41    14.378     1.414     50.443       0        4.679                          
  TNFα       Median       0        0.776    25.784     13.647     38.192     16.04    3.104       0.49          0.583
  SD            0       3.722     109.392   28.535     81.853     32.08     14.226                          
  TNFβ       Median       0          0       5.751       0          0          0      14.509      0.77          0.635
  SD            0         0       24.398       0         0          0       66.487                          

DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue lymphoma, GI: gastrointestinal

\**P* values were calculated among lymphoma subtypes and normal controls.

\*\**P* values were calculated among lymphoma subtypes.

###### Cases included in this study.

  Histology    Total   Gastrointestinal lesion  
  ----------- ------- ------------------------- ----
  DLBCL         55                8              23
  FL            36               18              17
  MALT          15               11              4
  Others        42                                
  Normal        21                                

DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma,

MALT: mucosa-associated lymphoid tissue lymphoma.
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